BUND FINANCE › Stocks › VRTX
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +2.71% above its 50-day average.
- It is +10.84% above its 200-day average (long-term uptrend).
- It sits at 79% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$7.6B | US$8.9B | US$9.9B | US$11.0B | US$12.0B |
| Net income | US$2.3B | US$3.3B | US$3.6B | −US$535.6M | US$4.0B |
| EPS (diluted) | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 |
| Gross margin | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% |
| Operating margin | 36.7% | 48.2% | 38.8% | -2.1% | 34.8% |
| Net margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% |
| Free cash flow | US$2.4B | US$3.9B | US$3.3B | −US$790.3M | US$3.2B |
| Total debt | US$967.4M | US$899.7M | US$808.4M | US$1.7B | US$2.0B |
| Cash | US$6.8B | US$10.5B | US$10.4B | US$4.6B | US$5.1B |
Compound annual growth: revenue 12.2% · net income 14.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 34.5x | 26.2x | 27.1x |
| EV / EBITDA | 27.4x | 57.2x | 16.5x |
| Operating margin | 33.9% | — | 3.6% |
| Net margin | 30.6% | — | -0.0% |
| Debt / equity | 0.57 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitryp…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice